RxTrials Institute Drug Pipeline Alert

More than two-thirds of HIV patients taking Pfizer’s Selzentry and GlaxoSmithKline’s Combivir had the viral load in their blood suppressed to undetectable levels, according to Phase III trial data.

The re-analysis of the Phase III study compared two combinations — 300 mg of Selzentry (maraviroc) twice daily plus Combivir (zidovudine/lamivudine) and the second therapy of 600 mg of Bristol-Myers Squibb’s (BMS) Sustiva (efavirenz) once daily plus Combivir — in treatment-naive CCR5-tropic HIV-1 infected patients.

The re-analysis showed that 68 percent of patients in the Selzentry arm and 68 percent of patients in the Sustiva arm had undetectable levels of the virus, Pfizer says in a statement.